[ad_1]
NIPER scientists based in Hyderabad claimed to have discovered that Nimbolide, a chemical compound derived from the leaves and flowers of Neem, can effectively fight bad cancer.
They are approaching various organizations such as Biotechnology Departments, AYUSH and Science and Technology for Funding to continue research and undertake clinical trials, said scientist Chandraiah Godugu.
Scientists at the National Institute of Pharmaceutical Education and Research (NIPER) found that Nimbolide significantly inhibited the growth of bad cancer.
Currently, further studies were underway to facilitate clinical trials, says Godugu.
It could also become the least expensive anti-cancer drug by implementing advanced production technology processes because Neem was ubiquitous in India, the scientist said.
In addition to his anti-cancer property, he may prove to be a promising chemo-preventive agent, Sai Godugu, who is part of the research program
He said that although various parts of 39, a Neem plant were used traditionally to cure multiple disorders, scientific evidence of their reasoning was lacking.
"We have recently proven the anticancer efficacy of Nimbolide in bad cancer by new molecular pathways, it induces cell death and inhibits the proliferation of cancer cells.
" We have discovered that Nimbolide significantly inhibited the growth of bad cancer and triple negative bad cancer cells … ", he told PTI.The Neem tree (Azadirachta Indica) has great value in the Indian system of medicine and holds a significant place in Ayurveda.
It has many properties, as it is anti-microbial, anti-cancer, anti-diabetic and anti-inflammatory, says the scientist. [19659002] "Its anti-cancer activity has been widely explored, mainly thanks to its active component Nimbolide, an innovative compound whose pre-clinical efficacy is promising against multiple types of cancer," said Godugu.
Cepe ndant, the clinical translation has been hampered due to the unexplored pharmacokinetics of this new molecule with immense potential for clinical translation, he added.
In order to solve the enigma of the oral bioavailability and pharmacokinetics of Nim bolide, NIPER has made a team of experts in the field of pharmacology and pharmaceutical badysis including Shandilya Baira, Amit Khurana, Jaganmohan Somagoni, Srinivas R, Godugu, MVN Kumar Talluri.
"Nimbolide can even reduce the serious side effects badociated with chemotherapeutic drugs.As it shows anticancer activity by attacking multiple pathways, the chances of drug resistance are very low.
" It may turn out beneficial against recurrent tumor that poses the challenge of drug resistance and even kill dormant and resistant cancer stem cells. "The scientist said.
He said that they can expect a clinical translational value formulation in the next four to five years with the entry of the most promising formulation to the Phase I clinical trials.
NIPER, Hyderabad, is an "Institute of National Importance" with proclaimed goals of becoming Center of Excellence for Advanced Research in Pharmaceutical Sciences.
Source link
